Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)

NCT07357519 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed / Refractory Osteosarcoma

Interventions

DRUG: LNTH2403 Phase 1 dose
DRUG: Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D).

Sponsor

Lantheus Medical Imaging